A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS9595-TPS9595 ◽  
Author(s):  
Anna Maria Di Giacomo ◽  
Alessia Covre ◽  
Pietro Taverna ◽  
Sandra Coral ◽  
Giovanni Amato ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Second Generation ◽  
Phase Ib ◽  
Hypomethylating Agent ◽  
Dna Hypomethylating Agent

Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine

1988 ◽  
Vol 6 (3) ◽  
pp. 185-200 ◽  
Author(s):  
Deborah L. Trainer ◽  
Thomas Kline ◽  
Gary Hensler ◽  
Russell Greig ◽  
George Poste
Keyword(s):  
Melanoma Cells ◽  
Clonal Analysis ◽  
B16 Melanoma ◽  
B16 Melanoma Cells ◽  
Hypomethylating Agent ◽  
Dna Hypomethylating Agent

scholarly journals A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

2019 ◽  
Vol 12 (6) ◽  
pp. 828-835 ◽  
Author(s):  
Lu Si ◽  
Xiaoshi Zhang ◽  
Yongqian Shu ◽  
Hongming Pan ◽  
Di Wu ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Chinese Patients ◽  
Second Line ◽  
Second Line Therapy ◽  
Phase Ib ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document